2022 Outlook Includes Acceptance Of US IND For Head And Neck Squamous Cell Carcinoma In Q1 Of 2022
13/01/2022 12:34
Jan 13 (Reuters) - Achilles Therapeutics PLC 698y.F :
* ACHILLES THERAPEUTICS PLC - 2022 OUTLOOK INCLUDES ACCEPTANCE OF US IND FOR
HEAD
AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) IN Q1 OF 2022
* ACHILLES THERAPEUTICS PLC - PLANS TO USE VELOS PROCESS 2 FOR MANUFACTURE
OF CNET
PRODUCTS IN UK, FRANCE, GERMANY, SPAIN, AND US
Source text for Eikon: ID:nGNX85Dd7k
Further company coverage: 698y.F
Recent news on Achilles Therapeutics
See all newsBrief: Achilles Therapeutics Announces Sale Of Technology Assets To Astrazeneca
Brief: Achilles Therapeutics Receives Approval To Transfer To Nasdaq Capital Market
Achilles gains on plans to explore strategic options
Brief: Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy
Brief: Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement